PROTAGONIST THERAPEUTICS

Serial Number 98319631
731

Registration Progress

Application Filed
Dec 18, 2023
Under Examination
Oct 22, 2024
Approved for Publication
Aug 27, 2024
Published for Opposition
Aug 27, 2024
Registered

Trademark Image

PROTAGONIST THERAPEUTICS

Basic Information

Serial Number
98319631
Filing Date
December 18, 2023
Published for Opposition
August 27, 2024
Drawing Code
3

Status Summary

Current Status
Active
Status Code
731
Status Date
Oct 7, 2025
Application
Pending
Classes
005 042 044

Rights Holder

Protagonist Therapeutics, Inc.

03
Address
7707 Gateway Blvd. Suite 210
Newark, CA 94560

Ownership History

Protagonist Therapeutics, Inc.

Original Applicant
03
Newark, CA

Protagonist Therapeutics, Inc.

Owner at Publication
03
Newark, CA

Legal Representation

Attorney
Frances M. Jagla

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

21 events
Date Code Type Description Documents
Oct 8, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 7, 2025 EX2G S SOU EXTENSION 2 GRANTED Loading...
Oct 7, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 7, 2025 EXT2 S SOU EXTENSION 2 FILED Loading...
Apr 16, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 15, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Apr 15, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Apr 15, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 22, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 27, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 27, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 7, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jul 18, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 17, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jul 17, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jul 17, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jul 17, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jul 16, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 26, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 26, 2024 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Dec 18, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of oncological, hematological, inflammatory and autoimmune disorders, rare and orphan disorders, endocrine disorders
Class 042
Scientific and medical research relating to oncological, hematological, inflammatory and autoimmune disorders, rare and orphan disorders, endocrine disorders
Class 044
Providing online healthcare and medical information to patients and healthcare providers relating to oncological, hematological, inflammatory and autoimmune disorders, rare and orphan disorders, endocrine disorders

Additional Information

Design Mark
The mark consists of the word "Protagonist" above the word "Therapeutics" to the left of the words is a DNA double helix.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005 042 044

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"